Company profile
Werewolf Therapeutics, Inc.
NASDAQ:HOWLBiotechnology: Pharmaceutical Preparations
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06939283 | phase1_2 | active_not_recruiting | 2025-05-07 | 2028-08-01 | Werewolf Therapeutics, Inc. | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma |
| NCT05479812 | phase1 | completed | 2022-05-20 | 2026-04-22 | Werewolf Therapeutics, Inc. | Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors |
| NCT05678998 | phase1 | completed | 2022-12-06 | 2024-12-23 | Werewolf Therapeutics, Inc. | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma |
FDA applications (0)
No records yet.